- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03863132
Nøyaktig vurdering av nytte med optimal medisinsk behandling med eller uten transkateterventil Reparasjon av PARADOKSAL lavstrøms lavgradient aortastenose (REBOOT-PARADOX)
Optimal medisinsk behandling med eller uten ventilreparasjon hos pasienter med symptomatisk paradoksalt lav-flow, lavgradient aortastenose - en multisenter, randomisert sammenligning
Aim of this study is to evaluate whether microsurgical repair or replacement of the aortic valve is a treatment option for a subgroup of patients suffering from aortic Stenosis.
Studieoversikt
Detaljert beskrivelse
Stenosis of the aortic valve leads to a narrowing of the valve, consequently to low blood flow from the heart into the Aorta, and is associated with symptoms like fatigue, breathlessness, dizziness, fainting, and chest pain. For many of the patients suffering from severe aortic stenosis surgical or catheter-assisted repair or replacement of the damaged aortic valve has been proven to be a safe and effective treatment option.
Probably about 20-30% of patients suffering from severe aortic stenosis display a deviation from the usually observed disease pattern: These patients do not show the typical high pressure difference between the left ventricle (heart chamber) and the aorta (transvalvular gradient; "paradoxical" low flow/low gradient aortic stenosis). For these patients it is not yet clear, if microsurgical repair of the aortic valve (transcatheter aortic valve repair - TAVR) should be a treatment option as well.
REBOOT-PARADOX evaluates whether TAVR is advantageous compared to optimal medical Treatment alone for patients suffering from paradoxical aortic stenosis. Two thirds of the participating patients will be treated by TAVR, one third will receive medical Treatment alone.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Milan, Italia, 20089
- Humanitas Mirasole S.P.A
-
Pisa, Italia, 56126
- Azienda Ospedaliero Universitaria Pisana
-
-
-
-
-
Zurich, Sveits, 8091
- Universitätsspital Zürich, Universitätres Herzzentrum Zürich
-
-
-
-
Baden-Wurttemberg
-
Tübingen, Baden-Wurttemberg, Tyskland, 72076
- Universitätsklinikum Tübingen
-
-
Bavaria
-
München, Bavaria, Tyskland, 80636
- Deutsches Herzzentrum München
-
München, Bavaria, Tyskland, 81377
- Klinikum der Universität München-Großhadern
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Tyskland, 20246
- Universitäres Herz- u. Gefäßzentrum Hamburg
-
-
Hesse
-
Bad Nauheim, Hesse, Tyskland
- Kerckhoff-Klinik GmbH
-
-
Lower Saxony
-
Bad Bevensen, Lower Saxony, Tyskland, 29549
- Herz- und Gefäßzentrum Bad Bevensen
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, Tyskland, 18057
- Universitätsmedizin Rostock, Klinik und Poliklinik für Kardiologie
-
-
North Rhine-Westphalia
-
Bad Oeynhausen, North Rhine-Westphalia, Tyskland, 32545
- Herz- und Diabeteszentrum Nordrhein-Westfalen Bad Oeynhausen
-
Cologne, North Rhine-Westphalia, Tyskland, 50937
- Herzzentrum der Universität Köln
-
-
Rhineland-Palatinate
-
Ludwigshafen am Rhein, Rhineland-Palatinate, Tyskland
- Klinikum der Stadt Ludwigshafen a. Rh.
-
-
Saxony
-
Leipzig, Saxony, Tyskland
- Herzzentrum Leipzig
-
-
Schleswig-Holstein
-
Bad Segeberg, Schleswig-Holstein, Tyskland
- Segeberger Kliniken, Herzzentrum
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- I1. Patients with symptomatic native aortic valve stenosis and age ≥18 years
- I2. Aortic valve area (AVA) ≤ 1 cm2 or indexed AVA ≤ 0.6 cm2/m2, mean aortic gradient < 40 mmHg and stroke volume index (SVI) < 35ml/m2
- I3. Left ventricular ejection fraction ≥ 50%
- I4. MDCT aortic valve calcium score men > 2000AU, women > 1200AU OR the likelihood criteria are fulfilled (symptoms without other explanation and LV hypertrophy; age < 70 yrs., AVS < 0.8 cm2; SVI < 35ml/m2 confirmed by 3D TOE, MRI or invasive; reduced LV longitudinal function without other reason)
- I5. Heart team agrees on eligibility for TAVR
- I6. Written informed consent
- I7. Negative pregnancy test in women with childbearing potential
Exclusion Criteria:
- E1. Hemodynamic instability
- E2. Cardiogenic shock
- E3. Pre-existing mechanical or bio-prosthetic valve in any position
- E4. Concomitant severe valvular heart disease
- E5. Pre-existing or active endocarditis
- E6. Need for heart surgery due to other conditions
- E7. Aortic valve is congenital unicuspid or congenital bicuspid
- E8. Hypertrophic cardiomyopathy with or without obstruction
- E9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- E10. Acute myocardial infarction within 1 month before intended AS-treatment
- E11. Renal replacement therapy
- E12. Estimated life expectancy < 24 months (730 days) due to carcinomas end stage liver disease or renal disease
- E13. Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- E14. Patient refuses aortic valve repair
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: TAVR Group
Patients will be treated by transcatheter aortic valve repair (TAVR). |
Repair of defective aortic valve by microsurgical Intervention. |
|
Ingen inngripen: Medical Treatment Group
Patients will receive optimal medical treatment alone. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to death
Tidsramme: 24 months after last-patient-in
|
All-cause mortality |
24 months after last-patient-in
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cardiovascular mortality
Tidsramme: 5 years after index treatment
|
Death because of cardiovascular events |
5 years after index treatment
|
|
Re-hospitalization due to heart failure
Tidsramme: 5 years after index treatment
|
Number of hospital stays after randomization |
5 years after index treatment
|
|
Incidence of neurological events - incidence of strokes
Tidsramme: 5 years after randomization
|
Number of strokes |
5 years after randomization
|
|
Incidence of neurological Events - incidence of transient ischaemic attacks
Tidsramme: 5 years after randomization
|
Number of transient ischaemic attacks |
5 years after randomization
|
|
Cardiac functionality - left ventricular function
Tidsramme: 5 years after randomization
|
Echocardiographic measurement of left ventricular ejection fraction in % |
5 years after randomization
|
|
Cardiac functionality - aortic valve hemodynamics
Tidsramme: 5 years after randomization
|
Measurement of aortic pressure in mmHg |
5 years after randomization
|
|
Patients' quality of life
Tidsramme: 5 years after randomization
|
EQ5D-score in % |
5 years after randomization
|
|
Device reliability
Tidsramme: 5 years after randomization
|
Number of reinterventions (TAVR arm only) |
5 years after randomization
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Steffen Massberg, Prof. Dr., University Clinic Munich
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- REBOOT-PARADOX
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .